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Abstract Purpose: Metastasis is the main cause of mortality in non–small cell lung cancer
(NSCLC) patients. Genes that can discriminate the invasion ability of cancer cells
may become useful candidates for clinical outcome prediction. We identify inva-
sion-associated genes through computational and laboratorial approach that sup-
ported this idea in NSCLC.
Experimental Design: We first conducted invasion assay to characterize the invasion
abilities of NCI-60 lung cancer cell lines. We then systematically exploited NCI-60
microarray databases to identify invasion-associated genes that showed differential
expression between the high and the low invasion cell line groups. Furthermore,
using the microarray data of Duke lung cancer cohort (GSE 3141), invasion-associ-
ated genes with good survival prediction potentials were obtained. Finally, we vali-
dated the findings by conducting quantitative PCR assay on an in-house collected
patient group (n = 69) and by using microarray data from two public western co-
horts (n = 257 and 186).
Results: The invasion-associated four-gene signature (ANKRD49, LPHN1, RABAC1, and
EGLN2) had significant prediction in three validation cohorts (P = 0.0184, 0.002, and
0.017, log-rank test). Moreover, we showed that four-gene signature was an indepen-
dent prognostic factor (hazard ratio, 2.354, 1.480, and 1.670; P = 0.028, 0.014, and 0.033),
independent of other clinical covariates, such as age, gender, and stage.
Conclusion: The invasion-associated four-gene signature derived from NCI-60 lung
cancer cell lines had good survival prediction power for NSCLC patients. (Clin Cancer
Res 2009;15(23):7309–15)
Lung cancer is the most common cause of cancer deaths world-
wide and non–small cell lung cancer (NSCLC) is the major
dominant cell type (1, 2). For the early-stage lung cancer, sur-
gery remains the treatment of choice. But the widespread metas-
tasis of lung cancer often defeats this treatment and up to 40%
of such patients may relapse within 5 years (3, 4). Therefore,
identification of patients at the high risk of recurrence or metas-
tasis after resection may help improve the management of
NSCLC patients.
Migration and invasion ability of cancer cells are the most crit-
ical initial events of cancer metastasis (5). It is important to find
gene signatures that may distinguish the invasion abilities of
cancer cells to invade (6). Many studies on cancer metastasis
have identified several molecules participating in tumor cell in-
vasion and metastasis in different types of cancers (7). Microar-
ray data have been widely used in discovering tumor subtypes,
finding molecular characterization about tumor stage and meta-
static status, and predicting patient survival (8–10). Various
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platforms of microarray have been applied to profile the gene
expression patterns of the panel of NCI-60 cell lines (11).
We focused on the subset of the nine lung cancer cell lines
in NCI-60 gene expression data set and used one set of public
microarray data of western lung cancer patients to derive an
invasion-associated gene signature for survival prediction. We
validated the findings by three independent NSCLC cohorts.
Our computational approach integrated both invasion profiles
of lung cancer cell lines and gene expression profiles, and our
results provided clues to interpret the mechanism of cancer
metastasis.
Materials and Methods
Taiwanese cohort: patients and tissue specimen collections. A cohort
that consisted of 69 patients from Taiwan was used for quantitative
PCR (qPCR) validation conducted in our lab. Frozen specimens of lung
cancer tissue came from 69 patients who underwent surgical resection
of NSCLC at the Taichung Veterans General Hospital (VGHTC) between
December 1999 and December 2003. The cohort included 27 adenocar-
cinomas, 36 squamous cell carcinomas, and 6 other types of cancer. The
patients had not received adjuvant chemotherapy. The study was ap-
proved by the institutional review board of the hospital. Written in-
formed consent was obtained from all patients.
Cell culture. The nine NCI-60 lung cancer cell lines (A549/ATCC,
NCI-H460, NCI-H23, NCI-H322M, EKVX, NCI-H226, NCI-H522,
HOP-62, and HOP-92) were purchased from the National Cancer In-
stitute. The cells were grown in tissue culture flasks at 37°C in 5%
CO2 in RPMI 1640 with 2 mmol/L L-glutamine and 10% fetal bovine
serum.
Matrigel invasion assay. The invasion capacities for cell lines were
examined by using membrane invasion culture system to confirm
their invasion ability, respectively. A HTS FluoroBlok insert contain-
ing 8-μm pores (Falcon, Becton Dickinson) was coated with 30 μg
Matrigel (BD). The cells were suspended in RPMI 1640 containing
10% fetal bovine serum and seeded into the upper wells of the
chamber (2.5 × 104 per well). After incubating for 24 h at 37°C,
the membrane of the Transwell will be fixed for 10 min at room
temperature with methanol and stained for 30 min with 50 μg/mL
propidium iodide (Sigma) and the cell number in each blot was
counted under a microscope with Analytical Imaging Station system
(Imaging Research, Inc.).
Cell line gene expression data. We used two microarray gene expres-
sion profiling data sets for NCI-60 cell lines generated by Gene Logic
using Affymetrix U95 and U133, respectively. The mapping of probes
between U133 and U95 platforms was provided by Affymetrix.9 The
data sets were downloaded from the National Cancer Institute's Devel-
opmental Therapeutics Program Web site.10
Public NSCLC cohorts. The NSCLC cohort we used to derive gene
signature consisted of lung cancer patients from the Duke University.
Gene expression of 111 lung tumor tissues was profiled by using
HU133plus2 Affymetrix chip (12). We retrieved the data from the Gene
Expression Omnibus (GSE 3141). Intensity values were log transformed
to a base 2 scale.
The two western cohort data sets used for validation came from
Shedden et al. (13). The patients were from four institutions, University
of Michigan Cancer Center (UM), Moffitt Cancer Center (HLM), Me-
morial Sloan-Kettering Cancer Center (MSK), and the Dana-Farber Can-
cer Institute (CAN/DF), and divided into two cohorts, UM+HLM and
MSK+CAN/DF, as in Shedden et al. We preprocessed the microarray data
by normal score transformation.
The real-time reverse transcription-qPCR analysis. The expression of
four signature genes and two control genes (TBP for cell lines and
GAPDH for tissue specimens) was measured by reverse transcription-
qPCR (RT-qPCR) with specific Taqman probes and primer sets; the
transcripts were amplified with Taqman One-Step RT-PCR Master
Mix Reagent (Applied Biosystems) and a detection system (ABI
Prism 7900HT, Applied Biosystems). Gene expression was quanti-
fied in relation to the expression of the respective control gene with
the use of sequence detector software and the relative quantification
method (Applied Biosystems). The choice of TBP and GAPDH as
the internal control for real-time RT-PCR is based on their invari-
ance of expression in cancer cell lines and clinical cancer specimens
(14, 15).
Survival analysis. The association between survival and each gene
expression profile from microarray is evaluated by univariate Cox pro-
portional hazard regression analysis. A linear combination of the gene
expression levels weighted by the regression coefficients was used to
calculate the risk score for each patient.
More specifically, a patient's risk score was calculated as the sum
of the levels of expression of each gene measured by microarray
multiplied by the corresponding Cox regression coefficients. Patients
were classified as having a high-risk signature or a low-risk gene
signature, with the median of risk score as the threshold value. Sur-
vival curves for both groups were obtained by the Kaplan-Meier
method and compared using the log-rank test. Multivariate Cox pro-
portional hazard regression analysis with stepwise selection was
used to evaluate independent prognostic factors associated with pa-
tient survivals, taking the gene signature, age, sex, stage, and histol-
ogy as the covariates.
Except for the two places noted below, all tests were two sided, and a
P value of <0.05 was considered statistically significant. One-sided tests
were used in showing the consistency between qPCR data and the mi-
croarray data (‡P values; Table 1), and in one-sided log-rank test (P va-
lues of UM+HLM and MSK+CAN/DF cohorts) where the hypothesis of
interest is the one-sided hypothesis that the survival time is longer for
patients with the low-risk gene signature than that for patients with the
high-risk signature, note the two-sided hypothesis that the survival time
is different between the low-risk signature and the high-risk signature
(16, 17).
Translational Relevance
Metastasis is the most life-threatening factor of
malignant cancers. The migration and invasion abil-
ity of cancer cells is the first critical factor of metas-
tasis. Because most treatment failure and death in
cancer patients are due to the highly metastatic po-
tential of the neoplasm, finding biomarkers that may
distinguish the invasive ability of different cancer
cells can lead to the discovery of new gene signature
to improve the prediction of patient survival. We
identify novel invasion-associated genes from the
nine lung cancer cell lines in the NCI-60 panel and
validate the results thrice: twice with large-scale
western lung cancer cohorts and once by our own
oriental data. Our study may provide clues to the
mechanism of cancer metastasis and pave ways
for effective clinical outcome prediction of lung
cancer.
9 http://www.affymetrix.com/support/technical/comparison_spreadsheets.
affx
10 http://dtp.nci.nih.gov/mtargets/download.html
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Results
Strategy of in silico microarray approach to derive invasion-
associated gene signature for outcome prediction of NSCLC
patients. The strategy of our approach is illustrated in Fig. 1.
Based on invasion ability of the nine lung cancer cell lines, we
divided them into two groups.We identified the invasion-associated
genes from two Affymetrix NCI-60 microarray gene expression
data sets by finding the genes with differential expression
between the high and the low invasion groups. To reduce effect
of microarray noises, we filtered out 50% of the probes with low
average expression readings in data preprocessing.
Table 1. Four-gene signature from nine lung cancer cell lines predicts survival of 111 NSCLC patients
Gene symbol UniGene ID Probe ID (P)* Correlation coefficient (P)† HR‡ (P)§ 95% CI of HR
ANKRD49 Hs.29052 219069_at (0.015) 0.571 (0.050) 0.578 (0.002) 0.410-0.818
RABAC1 Hs.11417 203136_at (0.005) 0.806 (0.004) 1.510 (0.020) 1.067-2.137
LPHN1 Hs.654658 219145_at (0.029) 0.728 (0.013) 0.775 (0.033) 0.614-0.980
EGLN2 Hs.515417 220956_s_at (0.048) 0.711 (0.016) 1.910 (0.041) 1.027-3.552
*P value was based on Student's t test for differential expression between the high and the low invasion cell lines at the given probe ID used in
the gene; U133plus2 microarray data were used.
†P values for the correlation coefficients were given to test if qPCR and the microarray data for the lung cancer cell lines have positive correlation
or not.
‡The HRs are reported for the high-risk signature versus the low-risk signature, as determined by training Duke cohort.
§Estimated by univariate Cox regression analysis in training Duke cohort.
Fig. 1. Schematic diagram for deriving the gene
signature. For details, see Materials and Methods and
Results. DTP, Developmental Therapeutics Program.
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To examine which genes from our cell line–based search may
lead to useful clinical biomarkers, we obtained a large-scale mi-
croarray data set for tumor samples of western NSCLC patients
together with patients' survival data from Gene Omnibus (GSE
3141), referred to as the Duke cohort (n = 111; ref. 12). We ap-
plied the univariate Cox proportional hazard method to each of
the invasion-associated genes obtained from cell line assay for
finding genes whose expressions across patients correlate well
with patient survival. Because genes with higher (lower) expres-
sion levels for high invasion cell lines are expected to be risk
(protective) genes, we further inspect the direction of correla-
tion with survival to identify genes consistent with their inva-
sion abilities. For the genes that bypassed the consistency
checking, we confirmed their expression pattern on nine cell
lines by qPCR assay on the nine cell lines. Finally, we validate
this in silico–derived gene signature in three independent co-
horts: two new U133plus2 microarray data of western NSCLC
cohort (CAN/DF+MSK, n = 186; UM+HLM, n = 257; ref. 13)
and a group of 69 Taiwanese NSCLC samples (VGHTC, n = 69)
by qPCR assay.
Invasion profile and in silico microarray analysis in lung
cancer panel of NCI-60 cell lines. We determined the inva-
sion ability of nine human NSCLC cell lines in NCI-60
(Fig. 2A) and found three cell lines, A549, HOP-62, and
HOP-92, with much higher invasion ability than the other
six cell lines (Fig. 2A). To find invasion-associated genes
from the U133plus2 NCI-60 microarray data set, gene ex-
pression profiles for the high and the low invasion groups
were compared by two-tailed t tests and confirmed with the
U95 NCI-60 microarray data set. A total of 110 genes were
found differentially expressed and their expression profiles
formed two clusters (see Fig. 2B, wherein the top panel
showed the expression profiles of 72 genes that correlated
negatively with the invasive ability of lung cancer cell lines,
whereas the bottom panel gave the expression profiles of 38
genes that correlated positively).
Survival-associated gene signatures. The 110 genes associat-
ed with the invasion activity were identified by in vitro invasion
assay on NSCLC cell lines and in silicomicroarray analysis. How
do they affect the clinical outcome of lung cancer patients? To
investigate this issue, we take advantage of the availability of
the Duke lung cancer cohort (12) and evaluated the correlation
between the expression of each gene and the patient survival by
univariate Cox proportional hazard regression. This analysis
was done to determine which genes may be associated with pa-
tient death. Protective genes have hazard ratio (HR) for death of
<1, whereas risk genes have HR for death of >1. Of the 110 in-
vasion-associated genes, 9 genes were found statistically signif-
icant. We further checked if the protective/risk gene assignment
was consistent with the direction of the invasion ability of the
gene and found five genes consistent. One gene probe was lo-
cated at a pseudogene site, which was not considered further.
Fig. 2. A, in vitro invasion activity profile of nine lung cancer cell lines in NCI-60. Columns, mean of the data (n = 3); bars, SD. B, heat map of 110 gene
expression profiles showing the differential expression between lowly invasive (group I) and highly invasive (group II) lung cancer cell lines.
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For the remaining four genes, ANKRD49 and LPHN1 are protec-
tive and RABAC1 and EGLN2 are risk genes (Table 1).
Risk scores were calculated by using the above four genes.
Risk prediction was calculated as the sum of the levels of expres-
sion of each gene measured by microarray, multiplied by the
corresponding Cox regression coefficients. Patients in high- or
low-risk group were classified by using the 50th percentile (me-
dian) of the risk score distribution (median, 3.84; range, 2.5-
6.68) as the cut point.
The Kaplan-Meier method was used to estimate overall surviv-
al distribution for each group. Patients with high-risk gene sig-
nature as predicted by the four-gene signature had shortened
median overall survival compared with patients with low-risk
gene signature (24.33 versus 36.59 months; P = 0.001, log-rank
test; Fig. 3A). The expression levels of these four candidate genes
in the nine lung cancer cell lines were validated by doing the RT-
qPCR assay and calculating the Pearson correlation between the
qPCR data with the U133plus2 microarray data (Table 1).
Clinical characteristics of the NSCLC cohort are summarized
according to their high or low risk of the four-gene signature
(Supplementary Table S1). Multivariate Cox regression analysis
with stepwise selection was used to search for independent
prognostic factors associated with survival. The risk score by
the four-gene signature was evaluated along with age, gender,
tumor stage, and cell type. Patients with the high-risk signature
had a higher risk for poor survival with adjusted HR of 2.35
[95% confidence interval (95% CI), 1.367-4.025; P = 0.002].
The four-gene signature was still a significant survival predictor
after adjusting for tumor stage (Table 2A).
Independent validation of gene signature from Taiwanese data
set by RT-qPCR and public western data set. To investigate to
what extent the four genes were also valuable predictors for
the Asian patients, we investigated the VGHTC cohort. We
took lung cancer specimens from each patient and quantified
the gene expression of four candidate genes by RT-qPCR to
compute the patient risk scores for each patient and then di-
vided patients into high- and low-risk groups in the same
way as was done in the Duke cohort. We found that Kaplan-
Meier survival curves for the high- and low-risk groups in
the VGHTC cohort were separable and the result was statis-
tically significant (P = 0.0184, log-rank test; Fig. 3B). To
show that inclusion of the four-gene signature in the clinical
model had useful survival prediction performance indepen-
dent of cancer stage, we conducted a multivariate Cox regres-
sion with backward deletion. From the initial set of five
variables (age, gender, stage, cell type, and four-gene signa-
ture), the final model contains only age, stage, and four-gene
signature (Table 2A).
Moreover, we validated the four-gene signature in two new
western cohorts (UM+HLM and CAN/DF+MSK). Kaplan-
Meier survival curves were significantly separable (UM+HLM:
P = 0.002, log-rank test; CAN/DF+MSK: P = 0.017, log-rank
test; Fig. 4A and B), and four-gene signature was significant by
multivariate Cox regression in both cohorts (Table 2B).
Fig. 3. Survival distributions of 111 patients in the Duke NSCLC cohort (A)
and 69 patients in the VGHTC NSCLC cohort (B).
Table 2. Multivariate Cox regression analysis
Variable HR (95% CI) P
A
Original cohort (n = 111)
Four-gene signature 2.346 (1.367-4.025) 0.002
Stage 1.466 (1.128-1.905) 0.004
VGHTC cohort (n = 69)
Four-gene signature 2.354 (1.098-5.046) 0.028
Age 1.065 (1.014-1.119) 0.013
Stage 1.943 (1.332-2.835) <0.001
B
UM and HLM cohort (n = 257)
Four-gene signature 1.480 (1.083-2.024) 0.014
Age 1.024 (1.008-1.041) 0.003
Stage 2.140 (1.775-2.58) <0.001
CAN/DF and MSK cohort (n = 186)
Four-gene signature 1.670 (1.042-2.678) 0.033
Age 1.029 (1.004-1.056) 0.025
Stage 2.161 (1.625-2.874) <0.001
C
Low risk in both signatures 1.000
High risk in any signatures 5.140 (1.091-24.203) 0.038
High risk in both signatures 7.547 (1.599-35.623) 0.011
Stage 2.423 (1.388-4.229) 0.002
Age 1.081 (1.013-1.153) 0.019
NOTE: Four-gene signature for (A) Duke and VGHTC and (B) UM
+HLM and CAN/DF+MSK NSCLC patients. (C) Multivariate Cox re-
gression of concomitant four-gene and five-gene signatures as
prognostic predictors in overall survival of VGHTC patients. Vari-
ables were selected through stepwise selection method.
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This reassures the clinical usefulness of our finding. The four
invasion-associated genes might be potential molecular targets
for lung cancer therapy.
Discussion
Many studies have developed useful gene signatures by ex-
amining only the gene profiling data of the patient specimens
that they can access to (18–20). Differing from these works,
our approach started with an in silico exploitation of the pub-
lic domain microarray databases to derive the gene signature
and concluded with the validation by our own clinical data as
well as two public western clinical data. The public data we
used in this report included two sets of NCI-60 cell line mi-
croarray gene expression data and three microarray gene ex-
pression data sets from a western patient cohort. We also
conducted qPCR in our lab. As the genomic research gets dee-
per and broader, it has become more and more difficult for
any research team to generate all sorts of data on their own.
Consequently, it is worth investigating methods of how to use
the public data such as Gene Expression Omnibus, which is
growing at an astonishingly fast pace. More and more such
in silico microarray and bioinformatic approaches are antici-
pated to foster the area of clinical genomics.
Previously, a five-gene signature (9), motivated by different
cell line invasion assay and microarray platform, was also ob-
tained for NSCLC. Although there is no overlap between the
four genes identified in this article and the five-gene signa-
ture, both achieve the same goal. Both signatures had signif-
icant prediction power in multivariate Cox regression. Using
both signatures, we stratified the VGHTC cohort into three
groups and generated Kaplan-Meier plots to show their sur-
vival differences (Fig. 4C). The combined signature is signif-
icant under multivariate Cox regression with stage, gender,
and age (Table 2B).
Among the four genes in our invasion-associated signature,
the expression of RABAC1 and EGLN2 was found higher in
high invasion lung cell lines, whereas that of LPHN1 and
ANKRD49 was found higher in low invasion lung cell lines.
RABAC1 (Rab acceptor 1) is a transmembrane protein, local-
ized to the late Golgi, which also called PRA1 (21). It was
involved with T-cell factor/β-catenin signaling and dephos-
phorylation of extracellular signal-regulated kinase 1/2 (22).
RABAC1 gene was highly expressed in breast, colon, lung,
and ovary cancers (23). Interestingly, RABAC1 activated NF-κB
signaling through latent membrane protein 1, which is an
EBV-encoded oncoprotein (24). Moreover, infection of EBV
was associated with several cancers (25), consistent with risk
effect of RABAC1 in our signature. The EGLN2 was known
as prolyl-hydroxylase-1, which acted like an oxygen sensor
to inhibit hypoxia-induced activation of hypoxia-inducible
factor-1α (26, 27). EGLN2 was also characterized as estrogen-
induced tag-6, which has been reported to promote cell
growth in breast cancer (28). It is likely that the function
of EGLN2 in tumor tissues may be dependent on the oxygen
level. LPHN1 encoded a member of the latrophilin 1, which
was a member of G protein–coupled receptors associated
with activation of neurons (29). Latrophilin 1 regulated cell
adhesion and neurotoxin secretion (30) and brain-specific
angiogenesis inhibitor 1. Brain-specific angiogenesis inhibitor
1 was widely expressed in both glial cells and neurons but
has low expression in glioma cell lines (31). The function
of ANKRD49 (ankyrin repeat domain 49) is little known.
However, ankyrin repeat, a motif of 30– to 34–amino acid
residues (32), was first identified in the sequence of yeast
Swi6p, Cdc10p, and Notch (33), and Notch signaling is
one important pathway in tumorigenic processes. Families
of ankyrin repeat proteins mediating protein-protein interac-
tion have been associated with development of human
Fig. 4. Survival distributions of 257 patients in the UM+HLM cohort (A) and
186 patients in the CAN/DF+MSK cohort (B). C, 69 patients in the VGHTC
NSCLC cohort using the concomitant four-gene signature and five-gene
signature.
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cancer (34). The tumor suppressor gene p16 (INK4A) was an
ankyrin repeat protein that inhibited cell cycle progression to
reduce proliferation of cancer cells (35).
We concluded that an invasion-associated gene signature de-
rived from NCI-60 lung cancer cell lines by our in silico micro-
array approach had good survival prediction power in NSCLC
patients. The signature requires only four genes. For clinical ap-
plications, the smaller number of genes in the signature may
have the greater potential of translating into practical methods
of lung cancer patient risk stratification and developing person-
alized therapy.
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